Combining protein therapy and focused ultrasound therapy can improve cancer treatment

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) with focused ultrasound (FUS) can significantly reduce tumor size and burden in prostate cancer models, according to a new study published in Advanced Science by researchers at Rice University and Vanderbilt University.